Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

N Gianotti, A Cozzi-Lepri, A Antinori, A Castagna, A De Luca, BM Celesia, M Galli, C Mussini, C Pinnetti, V Spagnuolo, A D'Arminio Monforte, F Ceccherini-Silberstein, M Andreoni, on behalf of Icona Foundation Study, mono-PI/r database Study Cohorts

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (PI/r-MT) with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r). Design: A multicenter cohort of HIV-infected patients with viral load (VL) ≤50 copies/mL, who underwent a switch from any triple combination therapy to PI/r-MT with either LPV/r or DRV/r. Methods: VL was assessed in each center according to local procedures. Residual viremia was defined by any HIV-RNA value detectable below 50 copies/mL by a Real-Time PCR method. Standard survival analysis was used to estimate the rate of TF (defined by virological failure or interruption of monotherapy or reintroduction of combination therapy). A multivariable Cox regression analysis with automatic stepwise procedures was used to identify factors independently associated with TF among nadir and baseline CD4+ counts, residual viremia, time spent with 100 cells/μL) and residual viremia (aHR = 1.48 [95% CI: 1.01-2.17] vs. undetectable VL) were independently associated to TF. Conclusions: Residual viremia and nadir CD4+ counts
Original languageEnglish
Article numbere0171611
JournalPLoS One
Volume12
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Lopinavir
Ritonavir
Viremia
viremia
refining
Treatment Failure
Refining
viral load
Viral Load
HIV
CD4 Lymphocyte Count
proteinase inhibitors
Protease Inhibitors
therapeutics
Survival Analysis
Regression analysis
Real-Time Polymerase Chain Reaction
quantitative polymerase chain reaction
regression analysis
Switches

Cite this

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. / Gianotti, N; Cozzi-Lepri, A; Antinori, A; Castagna, A; De Luca, A; Celesia, BM; Galli, M; Mussini, C; Pinnetti, C; Spagnuolo, V; D'Arminio Monforte, A; Ceccherini-Silberstein, F; Andreoni, M; Study, on behalf of Icona Foundation; Cohorts, mono-PI/r database Study.

In: PLoS One, Vol. 12, No. 2, e0171611, 2017.

Research output: Contribution to journalArticle

Gianotti, N, Cozzi-Lepri, A, Antinori, A, Castagna, A, De Luca, A, Celesia, BM, Galli, M, Mussini, C, Pinnetti, C, Spagnuolo, V, D'Arminio Monforte, A, Ceccherini-Silberstein, F, Andreoni, M, Study, OBOIF & Cohorts, M-PIDS 2017, 'Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients', PLoS One, vol. 12, no. 2, e0171611. https://doi.org/10.1371/journal.pone.0171611
Gianotti, N ; Cozzi-Lepri, A ; Antinori, A ; Castagna, A ; De Luca, A ; Celesia, BM ; Galli, M ; Mussini, C ; Pinnetti, C ; Spagnuolo, V ; D'Arminio Monforte, A ; Ceccherini-Silberstein, F ; Andreoni, M ; Study, on behalf of Icona Foundation ; Cohorts, mono-PI/r database Study. / Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. In: PLoS One. 2017 ; Vol. 12, No. 2.
@article{a8afcb5891284e9488c2e0e0bbec3d51,
title = "Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients",
abstract = "Objective: The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (PI/r-MT) with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r). Design: A multicenter cohort of HIV-infected patients with viral load (VL) ≤50 copies/mL, who underwent a switch from any triple combination therapy to PI/r-MT with either LPV/r or DRV/r. Methods: VL was assessed in each center according to local procedures. Residual viremia was defined by any HIV-RNA value detectable below 50 copies/mL by a Real-Time PCR method. Standard survival analysis was used to estimate the rate of TF (defined by virological failure or interruption of monotherapy or reintroduction of combination therapy). A multivariable Cox regression analysis with automatic stepwise procedures was used to identify factors independently associated with TF among nadir and baseline CD4+ counts, residual viremia, time spent with 100 cells/μL) and residual viremia (aHR = 1.48 [95{\%} CI: 1.01-2.17] vs. undetectable VL) were independently associated to TF. Conclusions: Residual viremia and nadir CD4+ counts",
author = "N Gianotti and A Cozzi-Lepri and A Antinori and A Castagna and {De Luca}, A and BM Celesia and M Galli and C Mussini and C Pinnetti and V Spagnuolo and {D'Arminio Monforte}, A and F Ceccherini-Silberstein and M Andreoni and Study, {on behalf of Icona Foundation} and Cohorts, {mono-PI/r database Study}",
year = "2017",
doi = "10.1371/journal.pone.0171611",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

AU - Gianotti, N

AU - Cozzi-Lepri, A

AU - Antinori, A

AU - Castagna, A

AU - De Luca, A

AU - Celesia, BM

AU - Galli, M

AU - Mussini, C

AU - Pinnetti, C

AU - Spagnuolo, V

AU - D'Arminio Monforte, A

AU - Ceccherini-Silberstein, F

AU - Andreoni, M

AU - Study, on behalf of Icona Foundation

AU - Cohorts, mono-PI/r database Study

PY - 2017

Y1 - 2017

N2 - Objective: The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (PI/r-MT) with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r). Design: A multicenter cohort of HIV-infected patients with viral load (VL) ≤50 copies/mL, who underwent a switch from any triple combination therapy to PI/r-MT with either LPV/r or DRV/r. Methods: VL was assessed in each center according to local procedures. Residual viremia was defined by any HIV-RNA value detectable below 50 copies/mL by a Real-Time PCR method. Standard survival analysis was used to estimate the rate of TF (defined by virological failure or interruption of monotherapy or reintroduction of combination therapy). A multivariable Cox regression analysis with automatic stepwise procedures was used to identify factors independently associated with TF among nadir and baseline CD4+ counts, residual viremia, time spent with 100 cells/μL) and residual viremia (aHR = 1.48 [95% CI: 1.01-2.17] vs. undetectable VL) were independently associated to TF. Conclusions: Residual viremia and nadir CD4+ counts

AB - Objective: The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (PI/r-MT) with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r). Design: A multicenter cohort of HIV-infected patients with viral load (VL) ≤50 copies/mL, who underwent a switch from any triple combination therapy to PI/r-MT with either LPV/r or DRV/r. Methods: VL was assessed in each center according to local procedures. Residual viremia was defined by any HIV-RNA value detectable below 50 copies/mL by a Real-Time PCR method. Standard survival analysis was used to estimate the rate of TF (defined by virological failure or interruption of monotherapy or reintroduction of combination therapy). A multivariable Cox regression analysis with automatic stepwise procedures was used to identify factors independently associated with TF among nadir and baseline CD4+ counts, residual viremia, time spent with 100 cells/μL) and residual viremia (aHR = 1.48 [95% CI: 1.01-2.17] vs. undetectable VL) were independently associated to TF. Conclusions: Residual viremia and nadir CD4+ counts

U2 - 10.1371/journal.pone.0171611

DO - 10.1371/journal.pone.0171611

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0171611

ER -